MX2008003378A - Integrated coil apparatus and method for using same - Google Patents
Integrated coil apparatus and method for using sameInfo
- Publication number
- MX2008003378A MX2008003378A MX/A/2008/003378A MX2008003378A MX2008003378A MX 2008003378 A MX2008003378 A MX 2008003378A MX 2008003378 A MX2008003378 A MX 2008003378A MX 2008003378 A MX2008003378 A MX 2008003378A
- Authority
- MX
- Mexico
- Prior art keywords
- signal
- electromagnetic
- waveform
- treatment apparatus
- electromagnetic treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000011282 treatment Methods 0.000 claims abstract description 122
- 230000037361 pathway Effects 0.000 claims abstract description 56
- 230000008878 coupling Effects 0.000 claims abstract description 46
- 238000010168 coupling process Methods 0.000 claims abstract description 46
- 238000005859 coupling reaction Methods 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 21
- 210000000056 organ Anatomy 0.000 claims abstract description 13
- 238000013178 mathematical model Methods 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 58
- 210000001519 tissue Anatomy 0.000 claims description 53
- 150000002500 ions Chemical class 0.000 claims description 37
- 239000003102 growth factor Substances 0.000 claims description 26
- 206010029113 Neovascularisation Diseases 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000033115 angiogenesis Effects 0.000 claims description 17
- 230000012010 growth Effects 0.000 claims description 16
- 230000008439 repair process Effects 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 15
- 210000002569 neuron Anatomy 0.000 claims description 15
- 238000012423 maintenance Methods 0.000 claims description 12
- 230000006866 deterioration Effects 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 10
- 230000005684 electric field Effects 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 8
- 238000000554 physical therapy Methods 0.000 claims description 8
- 210000002934 adrenergic neuron Anatomy 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 102000000584 Calmodulin Human genes 0.000 claims description 6
- 108010041952 Calmodulin Proteins 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 230000000739 chaotic effect Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000016396 cytokine production Effects 0.000 claims 3
- 238000013160 medical therapy Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000007620 mathematical function Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000008667 sleep stage Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 30
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 23
- 230000005672 electromagnetic field Effects 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000000541 pulsatile effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 5
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000003990 capacitor Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004980 dosimetry Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 208000002607 Pseudarthrosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000006739 dopaminergic cell death Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 210000004317 gizzard Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
An apparatus and method for electromagnetic treatment for treatment of molecules, cells, tissues, and organs comprising:configuring at least one waveform according to a mathematical model having at least one waveform parameter, said at least one waveform to be coupled to a target pathway structure (STEP 101);choosing a value of said at least one waveform parameter so that said at least waveform is configured to be detectable in said target pathway structure above background activity in said target pathway structure (STEP 102);generating an electromagnetic signal from said configured at least one waveform (STEP 103);integrating at least one coupling device with a positioning device to be placed in proximity to said target pathway structure (STEP 104);and coupling said electromagnetic signal to said target pathway structure using a coupling device (STEP 105).
Description
APPARATUS WITH INTEGRATED COIL AND METHOD FOR USING THE SAME
TECHNICAL FIELD This invention relates in general to an apparatus with integrated coil for electromagnetic treatment and to a method for using same to achieve the modification of growth, repair, maintenance and general behavior of cells and tissues by the application of coded electromagnetic information. More particularly, this invention relates to the application of a surgically non-invasive splice of highly specific electromagnetic signal patterns in any number of body parts. This invention also relates to the treatment. of tissues and living cells by modifying their interaction with their electromagnetic environment. The invention further relates to a method for modifying the growth, repair, maintenance, and general behavior of cells and tissues by the application of coded electromagnetic information. In particular, an embodiment according to the present invention relates to the use of an induction means such as a coil for supplying pulsed electromagnetic fields ("PEMF") to improve growth and repair of living tissue integrated with devices such as supports, blankets, beds, and wheelchairs, and together
with other therapeutic and well-being physical modalities such as ultrasound, positive or negative pressure, heat, cold, and massage. PREVIOUS TECHNIQUE It is now well established that the application of weak non-thermal electromagnetic fields ("EMF") can result in physiologically significant in vivo and in vitro bioeffects. EMF has been used in applications of bone reconstruction and bone consolidation. Waveforms that comprise low frequency and low power components are currently used in orthopedic clinics. The origins of the use of bone reconstruction signals began when considering that an electrical pathway can be a means through which bones can adaptively respond to EMF signals. A linear physicochemical procedure employing an electrochemical model of a cell membrane predicts a range of EMF waveform patterns for which bioeffects could be expected. Since the cell membrane was probably the target of EMF, it became necessary to find a range of waveform parameters for which an electrical field induced at the cell surface could be electrochemically coupled, such as voltage-dependent kinetics. The extension of this linear model
it also involved an analysis of Lorentz forces. A pulsatile radiofrequency signal ("PRF") derived from a continuous sine wave of 27.12 Hz used for deep tissue healing is known in the prior art of diathermy. A pulsatile successor of the diathermy signal was originally reported as an electromagnetic field capable of producing a non-thermal biological effect in the treatment of infections. Therapeutic applications of PRF have been reported for the reduction of pain and post-traumatic and post operative edema in soft tissues, wound healing, burn treatment and nerve regeneration. The application of EMF for the resolution of traumatic edema has increased its use in recent years. The results to date using the PRF in animal and clinical studies suggest that edema can be measured measurably from such electromagnetic stimulation. The EMF dosimetry considerations of the prior art have not taken into account the dielectric properties of the tissue structure as opposed to the properties of the isolated cells. In recent years, the clinical use of non-invasive radiofrequency PRF comprised the use of pulsatile bursts of a 27.12 MHz sine wave, where each pulsatile burst comprises an amplitude of sixty and
five microseconds, which has approximately 1,700 sinusoidal cycles per burst, and several repeat burst rates. This limits the frequency components that can be coupled to relevant dielectric trajectories in cells and tissue. Variable-time electromagnetic fields, comprising either rectangular, pseudo-rectangular, or both rectangular and pseudo-rectangular waveforms, such as pulse-modulated electromagnetic fields, and sinusoidal waveforms such as pulsating radio frequency fields that range from Several Hertz to a range of about 15 to about 40 MHz are clinically beneficial when used as adjunctive therapy for a variety of injuries and conditions of the locomotor system. At the beginning of the 60s, the development of modern therapeutic and prophylactic devices was stimulated by the clinical problems associated with bone fractures of pseudoarthrosis and late union. Preliminary work showed that an electrical pathway can be a means through which bone responds in an adaptable way to mechanical intervention. The preliminary therapeutic devices used implanted and semi-invasive electrodes that supplied direct current ("DC") to a fracture site. Subsequently developed
non-invasive technologies using electric and electromagnetic fields. These modalities were originally created to provide a non-invasive "non-contact" med to induce an electrical / mechanical waveform at a cell / tissue level. The clinical applications of these technologies in orthopedics have led to the approval of applications by regulatory bodies around the world for the treatment of fractures such as unbound and recent fractures, as well as for vertebral fusion. Currently, various EMF devices constitute the standard therapeutic arsenal of cynical orthopedic practice for the treatment of fractures that are difficult to heal. The success rate for these devices has been very high. The database for this indication is large enough to allow its recommended use as a safe, non-surgical, non-invasive alternative to a first bone graft. Additional clinical indications for these technologies have been reported in dually blinded studies for the treatment of avascular necrosis, tendonitis, osteoarthritis, wound repair, blood circulation and arthritis pain as well as for other injuries of the locomotor system. Cell studies have studied the effects of weak low frequency electromagnetic fields in both the signal transduction trajectories and in the synthesis of the growth factor. It can be shown that the EMF
stimulates the secretion of growth factors after a short duration of triggering type. The ion / ligand binding processes in a cell membrane are generally considered an initial structure of the E F target pathway. The clinical relevance to treatments for example of bone reconstruction, is an upregulation such as modulation, of the production of the factor of growth as part of the normal molecular regulation of bone reconstruction. Studies at the cellular level have shown effects on calcium ion transport, cell proliferation, release of Insulin Growth Factor ("IGF-II"), and expression of IGF-II receptor in osteoblasts. The effects on Insulin Growth Factor-I ("IGF-I") and IGF-II have also been demonstrated in rat fracture callus. Stimulation of transforming beta growth factor ("TGF-β") messenger RNA ("mRNA") with PEMF has been shown in a bone induction model in a rat. Studies have also shown upregulation of TGF-β mRNA by PEMF in the human osteoblast-like cell line designated MG-63, where increases in TGF-β, collagen, and osteocalcin synthesis were found. The PEMF stimulated an increase in TGF-β? both in hypertrophic and atrophic cells of human tissue of pseudoarthrosis. Additional studies showed an increase in both TGF-β? MRNA as in protein in crops
of osteoblast that result from a direct effect of EMF in a pathway that depends on calcium / calmodulin. Studies in cartilaginous cells have shown similar increases in TGF-β? MRNA and in the synthesis of EMF protein, demonstrating a therapeutic application for the reconstruction of joints. Several studies concluded that upregulation of growth factor production may be a common denominator in the tissue level mechanisms underlying electromagnetic stimulation. When specific inhibitors are used, EMF can act through a calmodulin-dependent pathway. It has been previously reported that specific PEMF and PRF signals, as well as weak static magnetic fields, modulate the binding of Ca2 + to CaM in a cell-free enzyme preparation. Additionally, upregulation of mRNA for BMP2 and BMP4 with PEMF has been demonstrated in osteoblast cultures and upregulation of TGF-β? in bone and cartilage with PEMF. However, the prior art in this field does not use an induction apparatus that supplies a signal in accordance with a mathematical model, which is programmable, lightweight, portable, disposable, implantable, and configured with, integrated within, or attached to at least one of, garments, accessories, footwear, bandages, anatomical supports, anatomical covers, clothing, cushions, mattresses, pads,
wheelchairs, therapeutic beds, therapeutic chairs, therapeutic and health maintenance devices such as vacuum assisted wound closure devices, mechanical and functional electrical stimulation devices and exercise devices, ultrasound, heat, cold, massage, and exercise. There is a further need for an induction apparatus for electromagnetic treatment and a method for using same that is light in weight, portable, implantable and that may be disposable. There is a further need for an induction apparatus and method for electromagnetic treatment that has decreased energy requirements and non-invasive characteristics that allow an improved signal to be integrated into surgical apposite, wound dressings, pads, seat cushions, mattress cushions , shoes, and any other garment and structure, juxtaposed to living tissues and cells, even to be integrated into the creation of a garment to provide an improved EF signal to any part of the body and to provide a signal in accordance with a mathematical model and be programmable. DESCRIPTION OF THE INVENTION An induction apparatus for electromagnetic treatment integrated into therapeutic and non-therapeutic devices and a method for using the
same for the therapeutic treatment of tissue and living cells by inductively coupling optimally configured waveforms to alter the interaction of tissues and living cells with their electromagnetic environment. In accordance with one embodiment of the present invention, an eligible body region is treated with a flow path comprising a succession of EMF pulses having a minimum amplitude characteristic of at least about 0.01 microseconds in a pulsed bursts envelope that it has between approximately 1 and approximately 100,000 pulses per burst, in which the voltage amplitude envelope of said pulsing burst is defined by a randomly varying parameter in which its instantaneous minimum amplitude is not less than its maximum amplitude by a factor of one to ten thousand. The repetition rate of the pulsatile burst can vary from about 0.01 to about 100,000 Hz. A mathematically definable parameter can also be used to define an amplitude envelope of said pulsatile bursts. By increasing a range of frequency components transmitted to relevant cellular trajectories, access to a wide range of biophysical phenomena applicable to consolidation mechanisms is advantageously achieved.
known, including improved enzymatic activity and release of growth factor and cytokine. According to one embodiment of the present invention, by means of the application of a random envelope, or another of high spectral density, to a pulsed burst envelope of mono or bipolar rectangular or sinusoidal pulses that induces peak electric fields between 10 ~ 6 and 10 volts per centimeter (V / cm), a more efficient and greater effect can be achieved in healing biological processes applicable to both soft and hard tissues in humans, animals and plants. A pulsed burst envelope of higher spectral density can be advantageously and efficiently coupled to physiologically relevant dielectric paths, such as, cell membrane receptors, ion binding to cellular enzymes, and potential general transmembrane changes thus modulating angiogenesis and neovascularization. Through the advantageous application of a high spectral density voltage envelope as a modulation definition parameter or pulse burst, the energy requirements for such modulated pulsatile bursts can be significantly less than those of an unmodulated pulse. This is due to the more efficient coupling of the frequency components to the relevant cellular / molecular process. Therefore, the
double advantage of improved transmission dosimetry to relevant dielectric trajectories and decreased energy requirements. A preferred embodiment according to the present invention utilizes a Signal to Noise Energy Ratio ("SNR Energy") procedure to configure bioeffective waveforms and incorporates miniaturized circuits and lightweight flexible coils. This advantageously allows a device that uses a SNR Energy procedure, miniaturized circuits, and lightweight flexible coils, to be completely portable and if it is desired to be constructed disposable and if it is further desired to be constructed implantable. Lightweight flexible coils can be an integral part of a positioning device such as surgical dressings, wound dressings, pads, seat cushions, cushions for mattresses, shoes, wheelchairs, chairs, and any other garment and structure, juxtaposed to tissue and living cells. By the advantageous integration of a coil into a positioning device, the therapeutic treatment can be provided to the tissue and living cells in a discreet and convenient manner. Specifically, bursts of broad spectral density of electromagnetic waveforms, configured to achieve maximum energy from
signal within a band pass of a biological target, to target path structures such as organs, tissues, cells and living molecules. The waveforms are selected using a single amplitude / energy comparison with that of noise, thermal in a target path structure. The signals comprise bursts of at least one of the sinusoidal, rectangular, chaotic and random waveforms, have a frequency content in a range of about 0.01 Hz to about 100 MHz in about 1 to about 100,000 bursts per second, and have a Burst repeat rate from approximately 0.01 to approximately 1000 bursts / second. The peak signal amplitude in a target path structure such as a tissue is found in a range of about? Μ? / Cm to about 100 mV / cm. Each signal burst envelope may be a random function that provides a means to accommodate different electromagnetic tissue healing features. A preferred embodiment according to the present invention comprises pulsating bursts of about 0.01 to about 100 milliseconds comprising symmetric or asymmetric pulses of about 1 to about 200 microseconds which are repeated at about 0.1 to about 100 kilohertz within the burst. The burst envelope is a function 1 / f
modified and applied at random repetition rates of between about 0.1 and about 1000 Hz. Fixed repetition rates between about 0.1 Hz and about 1000 Hz can also be used. An induced electric field of about 0.001 mV / cm to about 100 mV is generated. / cm. Another embodiment according to the present invention comprises a burst of about 0.01 milliseconds to about 10 milliseconds of high frequency sine waves, such as 27.12 MHz, which are repeated at about 1 to about 100 bursts per second. An induced electric field of about 0.001 mV / cm to about 100 mV / cm is generated. The resulting waveforms can be supplied by inductive or capacitive coupling. Another objective of the present invention is to provide an electromagnetic method for treating living cells and tissues comprising a broadband electromagnetic field of high spectral density. A further objective of the present invention is to provide an electromagnetic method of treating living cells and tissues comprising the amplitude modulation of a pulsed burst envelope of an electromagnetic signal that will induce coupling with a maximum number of relevant EMF-sensitive paths in cells or tissues.
An objective of the present invention is to configure an energy spectrum of a waveform by mathematical simulation using signal-to-noise ratio analysis ("SNR") to configure an optimized waveform to modulate angiogenesis and neovascularization and then coupling the waveform configured using a generating device such as ultra-light weight wire coils that are activated by a waveform configuration device such as a miniaturized electronic circuit. An object of the present invention is to provide flexible coils of light weight, which can be integrated into at least one of garments, accessories, footwear, bandages, anatomical supports, anatomical blankets, clothing, cushions, mattresses, pads, wheelchairs , therapeutic beds, therapeutic chairs, therapeutic and health maintenance devices such as vacuum assisted wound closure devices, mechanical and functional electrical stimulation devices and exercise devices and apposites to deliver the optimal dose of non-invasive pulsed electromagnetic treatment configured as shown above, for the repair and enhanced growth of living tissues in animals, humans and plants. Another object of the present invention is
providing a waveform configured by the SNR / energy analysis of a target path structure, programmable for example according to a timed dose schedule, a series of pulses, or some other random or patterned sequence. Another objective of the present invention is to generate a signal from a waveform configured by SNR / energy analysis of a target path structure, programmable for example according to a timed dose program, a series of pulses , or some other random or patterned sequence. Another objective of the present invention is to provide multiple coils, which provide a waveform configured by SNR / energy analysis of a target path structure, to increase the coverage area of the treatment. Another object of the present invention is to provide multiple coils that are simultaneously driven or that are sequentially conducted such as multiplexed, with the same or different waveforms configured optimally as shown above. A further objective of the present invention is to provide flexible, lightweight coils that focus the EMF signal to the affected tissue by incorporating the coils, which supply a configured waveform
by SNR / energy analysis of a target track structure, within garments of ergonomic support. It is still an additional objective of the present invention to use conductive yarn to create garments for daily use, and for exercise and sports that have integrated coils, which supply a waveform configured by the SNR / energy analysis of a track structure. objective, located in proximity to an anatomical objective. It is still a further object of the present invention to use lightweight flexible coils or conductive wire to deliver the EMF signal to the affected tissue by incorporating such conductive coils or wires as an integral part of various types of bandages, such as, of compression, elastic, compresses in cold and compresses in hot and that provide a form of wave configured by means of the analysis of SNR / energy. of an objective path structure. Another objective of the present invention is to employ several coils, which provide a waveform configured by the SNR / energy analysis of a target path structure, to increase the coverage area of the EMF. Another objective of the present invention is to construct a coil, which supplies a waveform configured by the SNR / energy analysis of a track structure
objective, using conductive wire. Another object of the present invention is to construct a coil, which supplies a waveform configured by SNR / energy analysis of a target path structure, using flexible fine conductive wire. Another objective of the present invention is to provide the same or different waveforms configured by the SNR / energy analysis of a target path structure, simultaneously or sequentially to single or multiple coils. It is still a further objective of the present invention to incorporate at least one coil in a surgical wound dressing to apply an improved EMF signal non-invasively and non-surgically, to utilize the surgical wound dressing in combination with standard wound treatment. Another object of the present invention is to construct the coils that supply a waveform configured by the SNR / energy analysis of a target via structure, for the easy joining and separation of the apposites, garments and supports using a means of union such as sailboat, an adhesive and any other means of temporary union such. Another object of the present invention is to provide coils that supply a waveform
configured by SNR / energy analysis of a target route structure, which are integrated with therapeutic beds, therapeutic chairs, and wheelchairs. Another objective of the present invention is to provide coils that provide a waveform configured by SNR / energy analysis of a target path structure, which are integrated with various therapeutic surfaces, such as pressure relieving, inflatable, fluid beds , visco-elastic and fluidized air and other support surfaces. Another object of the present invention is to provide coils that supply a waveform configured by the SNR / energy analysis of a target path structure that are integrated with therapeutic seat cushions such as inflatable, fluidized, foam cushions. Another object of the present invention is to provide coils that supply a waveform configured by the SNR / energy analysis of a target path structure, which are integrated with at least one of the upper layers of therapeutic mattresses, sheets, blankets , pillows, pillow blankets, and therapeutic devices that can apply static or intermnt pressure such as air filter suits.
Another objective of the present invention is to provide the inclusion of a fluid path to any surface, structure, or therapeutic device to improve the effectiveness of such therapeutic surfaces, structures or devices by providing a waveform configured by SNR / energy analysis of a target pathway structure. Another object of the present invention is to incorporate coils that supply a waveform configured by the SNR / energy analysis of a target track structure, in footwear such as shoes. Another objective of the present invention is to integrate at least one coil that supplies a waveform configured by SNR / energy analysis of an objective pathway structure, with a surface, structure or therapeutic device to improve the effectiveness of such surface, structure or therapeutic device. Yet another objective of the present invention is to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of a target pathway structure, with at least one of a therapeutic surface, a therapeutic structure, and a device therapeutic, to improve the effectiveness of at least one of the therapeutic surface, the therapeutic structure, and the therapeutic device, to avoid
loss and deterioration of cells and tissues. It is still another object of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of an objective pathway structure, with at least one of a therapeutic surface, a therapeutic structure, and a device Therapeutic, to improve the effectiveness of at least one of the therapeutic surface, the therapeutic structure, and the therapeutic device, to increase the activity of cells and tissues. It is still another object of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of an objective pathway structure, with at least one of, a therapeutic surface, a therapeutic structure, and a therapeutic device, to improve the effectiveness of at least one of the therapeutic surface, the therapeutic structure, and the therapeutic device, to increase the cell population. It is still another object of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of an objective pathway structure, with at least one of, a therapeutic surface, a therapeutic structure, and a therapeutic device, to improve the effectiveness of the
less one of, the therapeutic surface, the therapeutic structure and the therapeutic device, to avoid the deterioration of neurons. It is still another object of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of an objective pathway structure, with at least one of, a therapeutic surface, a therapeutic structure, and a therapeutic device, to improve the effectiveness of at least one of the therapeutic surface, the therapeutic structure and the therapeutic device, to increase the population of neurons. It is still another object of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of an objective pathway structure, with at least one of, a therapeutic surface, a therapeutic structure, and a therapeutic device, to improve the effectiveness of at least one of, the therapeutic surface, the therapeutic structure and the therapeutic device, to prevent the deterioration of adrenergic neurons in a cerebrofacial area. It is still another objective of the present invention to integrate at least one coil that supplies a waveform configured by the SNR / energy analysis of a
objective pathway structure, with at least one of, a therapeutic surface, a therapeutic structure, and a therapeutic device, to improve the effectiveness of at least one of the therapeutic surface, the therapeutic structure and the therapeutic device, to increase the population of adrenergic neurons in a cerebrofacial area. The foregoing and still other objects and advantages of the present invention will be apparent from the Brief Description of the Drawings, Detailed Description of the Invention, and Claims described hereinafter appended hereto. BRIEF DESCRIPTION OF THE DRAWINGS The preferred embodiments of the present invention will be described below in greater detail, with reference to the accompanying drawings: Figure 1 is a flowchart of an electromagnetic therapeutic treatment method for using the integrated coils within a positioning device according to an embodiment of the present invention; Figure 2 is a view of an electromagnetic treatment apparatus according to a preferred embodiment of the present invention; Figure 3 is a block diagram of the miniaturized circuits according to a modality
preferred of the present invention; Figure 4 depicts a waveform supplied to an objective track structure according to a preferred embodiment of the present invention; Figure 5 is a bar graph illustrating the results of PMF pre-treatment; Figure 6 is a bar graph illustrating the specific results of the PMF signal; and Figure 7 is a bar graph illustrating the chronic results of the PMF. MODES FOR CARRYING OUT THE INVENTION Variable time induced currents from PEMF or PRF devices flow in an objective pathway structure such as a molecule, cell, tissue, and organ, and it is these currents that are a stimulus to which the cells and tissues can react in a physiologically significant manner. The electrical properties of the target path structure affect the levels and distributions of the induced current. The molecules, cells, tissues and organs are all in an induced current pathway such as the cells in a gap junction contact. The ion or ligand interactions in the binding sites in macromolecules that can reside on a membrane surface are voltage-dependent, ie electrochemical, processes that can respond to a
induced electromagnetic field ("E"). The induced current reaches these sites by means of a surrounding ionic medium. The presence of cells in a current path causes an induced current ("J") to decay more rapidly over time ("J (t)"). This is due to an aggregate electrical impedance of the cells of membrane and time capacitance binding constants and other voltage-sensitive membrane processes such as membrane transport. Equivalent electrical circuit models have been derived representing various membrane and loaded interface configurations. For example, in the binding of calcium ("Ca2 +"), the change in the concentration of the bound Ca2 + at a binding site due to induced E can be described in a frequency domain by an impedance expression such as:
Zh (co) = Rion + - ^ - uLion which has the form of an equivalent electrical circuit of resistance-capacitance series. Where ? is the angular frequency defined as 2nr, where f is the frequency, i = -l1 2, Zb (co) is the junction impedance, and Rión and Ción are the equivalent junction resistance and the capacitance of a junction path of ion. The value of the equivalent union time constant, Tión = RiónCión, is related to a
constant of ion binding ratio, Kb, by ion-RiónCión-l / b. Therefore, the time constant characteristic of this path is. determined by ion-binding kinetics. The E induced from the PEMF or PRF signal can cause the current to flow within an ion binding path and affect the number of Ca21 ions bound per unit time. An electrical equivalent of this is a change in voltage across the equivalent junction capacitance C ± on, which is a direct measurement of the change in electrical charge stored by Cion. The electric charge is directly proportional to a surface concentration of Ca2 + ions at the binding site, ie the charge storage is equivalent to the storage of ions or other charged species on cell surfaces and junctions. The electrical impedance measurements, as well as the direct kinetic analysis of. junction rate constants, provide values for the time constants necessary for the configuration of a PMF waveform to coincide with a bandpass of the target path structures. This allows a required range of frequencies for any given induced E waveform to be optimally coupled to address the impedance, such as a bandpass. The ion union. to regulatory molecules is a
target of frequent EMF, for example the binding of Ca to calmodulin ("CaM"). The use of this route is based on the acceleration of tissue repair, for example bone repair, wound repair, hair repair, and repair of other molecules, cells, tissues, and organs that involves the modulation of released growth factors. in various stages of repair. Growth factors such as platelet-derived growth factor ("PDGF"), fibroblast growth factor ("FGF"), and epidermal growth factor ("EGF") are all involved at an appropriate stage of healing. Angiogenesis and neovascularization are also integral to tissue growth and repair and can be modulated by the PMF. All these factors are dependent on Ca / CaM. Using a Ca / CaM path, a waveform can be configured for which the induced energy is sufficiently above the background thermal noise energy. Under the correct physiological conditions, this waveform can have a physiologically significant bioeffect. The application of an SNR energy model to Ca / CaM requires knowledge of the electrical equivalents of the Ca2 + binding kinetics in CaM. Within the kinetics of
First-order binding, changes in the concentration of bound Ca2 + at the CaM binding sites over time can be characterized in a frequency domain by an equivalent binding time constant, T ion = RiónCión r where Rión and Ción they are the equivalent junction resistance and the capacitance of the ion junction pathway. Tión is related to an ion-binding ratio constant, Kb, by X
The published values for Kb can then be used in a cell layout model to evaluate SNR by comparing the voltage induced by a PRF signal with the thermal fluctuations in voltage at a CaM binding site. Using the numerical values for the PMF response, such as Vmax-6.5xl0 ~ 7 sec "1, [Ca2 +] -2.5μ ?, ?? - 30μ ?, [Ca2 + CaM] = KD ([Ca2 +] + [CaM ]), Kb = 665 sec "1 (t
mseg). Such a value for ion can be used in an equivalent electrical circuit for the ion junction while the SNR energy analysis can be carried out for any waveform structure. According to one embodiment of the present invention, a mathematical model can be configured to assimilate that thermal noise is present in all voltage-dependent processes and represents a minimum threshold requirement to establish an adequate SNR. The spectral energy density, Sn (co), of thermal noise can be expressed as:
Sn (a)) = 4kT Re [ZM (x,?)]
where Zm (x, o) is the electrical impedance of an objective path structure, x is a dimension of an objective path structure and Re denotes a real impedance part of a path structure > objective. Zm (x, co) can be expressed as: Re \ R¡ + Rg ZM (x, co) = tanh (yx)
This equation clearly shows that the electrical impedance of the target pathway structure, and the contributions of the extracellular fluid resistance ("Re"), the intracellular fluid resistance ("Rj.") And the intermembrane resistance ("Rg") which are electrically connected to the target path structures, all contribute to noise filtering. A typical procedure for the evaluation of SNR uses a unique value of a mean square noise (RMS) voltage. This is calculated by taking a square root of an integration of Sn (ü)) - 4kT Re [ZM (x, (ú)] over all relevant frequencies either to complete the membrane response, or for the bandwidth of a target path structure SNR can be expressed by a relationship:
where ?? (?) is the maximum voltage amplitude in each
frequency supplied by a selected waveform to the target path structure. One embodiment according to the present invention comprises a pulsed burst envelope having a high spectral density, such that the effect of the therapy is improved with the relevant dielectric paths, such as, the cell membrane receptors, the junction from ion to cellular enzymes and the general transmembrane potential changes. Accordingly, by increasing a number of frequency components transmitted to relevant cell trajectories, a wide range of biophysical phenomena is accessible, such as modulation of growth factor and cytokine release and ion binding in regulatory molecules applicable to mechanisms of known tissue growth. According to one embodiment of the present invention, the application of a random envelope, or another of high spectral density, to a pulse burst envelope of mono or bipolar rectangular or sinusoidal pulses that induces peak electric fields of between approximately 10"8 and approximately 100 V / cm, produces a greater effect in the biological healing processes applicable to both soft and hard tissues According to yet another embodiment of the present invention, by applying a high-spectral density voltage envelope as a parameter of definition
modulator or pulsed burst, the energy requirements for such pulsatile bursts of modulated amplitude may be significantly less than those of an unmodulated pulsatile burst containing pulses within a similar frequency range. This is due to a substantial reduction in the active cycle within sequences of repetitive bursts generated by the imposition of an irregular amplitude, and preferably randomly, over what would otherwise be a substantially uniform pulsating blister envelope. Accordingly, the double advantage of improved transmitted dosimetry to the relevant dielectric paths and decrease of energy requirements is achieved. With reference to Figure 1, wherein Figure 1 is a flow diagram of a method for delivering electromagnetic signals to target tissue path structures such as ions and ligands of animals, and humans for therapeutic and prophylactic purposes according to a embodiment of the present invention, a mathematical model is applied having at least one waveform parameter for configuring at least one waveform to be coupled to target path structures such as ions and ligands (Step 101). The configured waveform satisfies an SNR energy model in such a way that for a given and known objective path structure it is possible to select the
minus a waveform parameter so that a waveform is detectable in the target path structure above its background activity (Step 102) such as thermal fluctuations of the base line in voltage and electrical impedance in a structure of objective pathway that depend on a state of a cell and tissue, that is, if the state is at least one of rest, growth, replacement, and response to damage. A preferred embodiment of a generated electromagnetic signal comprises a burst of arbitrary waveforms having at least one waveform parameter that includes a plurality of frequency components ranging from about 0.01 Hz to about 100 MHz where the plurality of Frequency components satisfies an SNR energy model (Stage 102). A repetitive electromagnetic signal may be generated, for example inductively or capacitively, from said at least one configured waveform (Step 103). The electromagnetic signal is coupled to an objective pathway structure such as ions and ligands by the output of a coupling device such as an electrode or an inductor, located in close proximity to the target pathway structure (Step 104) using a device of positioning by integrating the coupling device with the positioning device (Stage
105). The coupling improves the modulation of binding of ions and ligands to regulatory molecules, tissues, cells, and organs. The coupling device can be integrated into the structure of the positioning device. The positioning device may be surgical dressings, wound dressings, pads, seat cushions, cushions for mattresses, shoes, wheelchairs, chairs, and any other garment and structure that can be juxtaposed with tissue and living cells. An advantage of the integration of the coupling device with a positioning device is that the therapeutic treatment can be administered unnoticed and can be administered anywhere at any time. Figure 2 illustrates a preferred embodiment of an apparatus according to the present invention. The device is autonomous, lightweight, and portable. A miniature control circuit 201 is coupled to an end of at least one connector 202 such as a cable, however the control circuit can also operate wirelessly. The opposite end of the at least one connector is coupled to a generating device such as an electrical coil 203. The miniature control circuit 201 is constructed so as to apply a mathematical model that is used to configure waveforms. The configured waveforms
they must satisfy an SNR energy model in such a way that for a given and known objective pathway structure, it is possible to select the waveform parameters that satisfy the SNR energy such that a waveform is detectable in the structure of the waveform. via objective over your background activity. A preferred embodiment according to the present invention applies a mathematical model for inducing a variable time magnetic field and a variable time electric field in an objective path structure such as ions and ligands, comprising bursts from about 0.1 to about 100 msec. , rectangular pulses of about 1 to about 100 microseconds repeating at about 0.1 to about 100 pulses per second. The peak amplitude of the induced electric field is between approximately 1 uV / cm and approximately 100 uV / cm, which varies according to a modified 1 / f function where f = frequency. A waveform configured using a preferred embodiment according to the present invention can be applied to an objective pathway structure such as ions and ligands for a preferred total exposure time of less than 1 minute to 240 minutes per day. However, other exposure times may be used. The waveforms configured by the miniature control circuit 201 are directed to a generating device 203
such as electric coils via connector 202 '. The generating device 203 supplies a pulsating magnetic field configured in accordance with a mathematical model that can be used to provide treatment to an objective path structure such as skin tissue. The miniature control circuit applies a pulsating magnetic field for a prescribed time and can be repeated automatically by applying the pulsating magnetic field for as many applications as necessary in a given period of time, for example ten times a day. The miniature control circuit can be configured to be programmable by applying pulsating magnetic fields during any time repeating sequence. A preferred embodiment according to the present invention can be positioned for hair treatment 204 being incorporated with a positioning device thereby making the unit autonomous. Coupling a pulsed magnetic field to an objective pathway structure such as beads and ligands, therapeutically and prophylactically reduces inflammation thereby reducing pain, and promotes healing in the treatment areas. When the electric coils are used as the generating device 203, the electric coils can be activated with a variable time magnetic field that induces a variable time electric field in a target path structure according to the law of
Faraday. An electromagnetic signal generated by the generator device 203 can also be applied using electrochemical coupling, wherein the electrodes are in direct contact with the skin or other electrically conductive outer perimeter of a target track structure. In yet another embodiment according to the present invention, the electromagnetic signal generated by the generating device 203 can also be applied using electrostatic coupling where there is an air gap between a generating device 203 such as an electrode, and an objective path structure such as ions and ligands. An advantage of the preferred embodiment according to the present invention is that its ultra-light weight coils and miniaturized circuits allow its use with common physical therapy treatment modalities and in any location where tissue growth is desired, relief of the pain, and scarring of tissues and organs. An advantageous result of the application of the preferred embodiment according to the present invention is that the growth, repair, and maintenance of the fabric can be achieved and improved at any place at any time. Yet another advantageous result of the application - of the preferred embodiment is that the growth, repair, and maintenance of molecules, cells, tissues, and organs can be achieved and improved at any place and at any time.
Figure 3 illustrates a block diagram of a preferred embodiment according to the present invention of a miniature control circuit 300. The miniature control circuit 300 produces waveforms that drive a generating device such as the wire coils described previously in Figure 2. The miniature control circuit can be activated by any means of activation such as an on / off switch. The miniature control circuit 300 has a power source such as a lithium battery 301. A preferred embodiment of the power source has a voltage output of 3.3 volts but other voltages can be used. In another embodiment according to the present invention the power source can be an external power source such as an electrical current output such as an AC / DC output coupled to the present invention for example by a connector and a cable. A switching power supply 302 controls the voltage to a microcontroller 303. A preferred mode of the microcontroller 303 uses a microcontroller of -8 bits at 4 MHz 303 but other bit-MHz combinations of microcontrollers may be used. The switching power supply 302 also supplies power to the storage capacitors 304. A preferred embodiment of the present invention utilizes capacitors of
storage that have a uF output of 220 but other outputs can be used. The storage capacitors 304 allow to supply high frequency pulses to a coupling device such as inductors (not shown). The microcontroller 303 also controls a pulse configurator 305 and a pulse phase time control 306. The pulse configurator 305 and the pulse phase time control 306 determine the pulse shape, burst width, the shape of the the burst envelope, and the repeat burst rate. An integral waveform generator, such as a sine wave or an arbitrary number generator, can be incorporated to provide specific waveforms. A voltage level conversion sub-circuit 308 controls an induced field supplied to a target path structure. The Hexfet 308 switching allows to supply pulses of random amplitude to the output 309 which directs a waveform to at least one coupling device such as an inductor. The microcontroller 303 may also control the total exposure time of a single treatment of an objective pathway structure such as a molecule, cell, tissue, and organ. The miniature control circuit 300 can be constructed to be programmable and apply a pulsating magnetic field for a prescribed time and to automatically repeat the application of the magnetic field
pulsatorio by as many applications as are necessary in a given period of time, for example 10 times a day. A preferred embodiment according to the present invention utilizes treatment times of about 10 minutes to about 30 minutes. The miniature control circuit 300 can also be integrated with a positioning device. The positioning device may also include at least one of a therapeutic surface, a therapeutic structure, and a therapeutic device, such as diathermy, ultrasound, TENS, massage, hot compress, cold compress, anatomically supporting surfaces, structures, and devices. With reference to Figure 4, a mode, according to the present invention, of a waveform 400 is illustrated. A drive 401 is repeated within a burst 402 having a finite duration 403. The duration 403 is such that the The operation cycle, which can be defined as a ratio of burst duration to signal period, is between approximately 1 to approximately 10 ~ 5. A preferred embodiment according to the present invention uses pseudo-rectangular drives of 10 microseconds per impulse 401 applied in a burst 402 for about 10 to about 50 ms that have a modified amplitude envelope 404 of 1 / f and with a finite duration 403 corresponding to a burst period of
between about 0.1 and about 10 seconds. Example 1 The SNR power procedure for the PMF signal configuration has been experimentally treated in calcium dependent myosin phosphorylation in a standard enzyme analysis. The reaction mixture without cells was selected so that the rate of phosphorylation was linear in time for several minutes, and for a concentration of sub-saturation of Ca 2+. This opens the biological window for Ca2 + / CaM to be sensitive to EMF. This system is not responsible for the PMF at the levels used in this study if Ca2 + is at saturation levels with respect to CaM, and the reaction is not delayed at a time range in minutes. The experiments were carried out using myosin light chain ("MLC") and myosin light chain kinase ("MLCK") isolated from turkey gizzard. The reaction mixture consisted of a basic solution containing 40 mM Hepes buffer, pH 7.0; 0.5 mM magnesium acetate; 1 mg / ml bovine serum albumin, 0.1% (weight / volume) of Tween 80; and 1 mM EGTA12. Free Ca2 + varied in the range of 1-7 uM. Once the Ca2 + buffer was established, 70 nM of freshly prepared CaM, 160 nM of MLC and 2 nM of MLCK were added to the basic solution to form a final reaction mixture. The low MLC / MLCK ratio allowed a linear time behavior in the
time range in minutes. This provided reproducible enzymatic activities and minimized pipette time errors. The reaction mixture was prepared fresh daily for each series of experiments and aliquoted in 100 ul portions into Eppendorff 1.5 ml tubes. All Eppendorff tubes containing the reaction mixture were kept at 0 ° C then transferred to a specially designed water bath maintained at 37 + 0.1 ° C by constant perfusion of preheated water by passing through a Fisher Scientific model 900 thermopermutator The temperature was monitored with a thermistor probe such as a Cole-Parmer model 8110-20, immersed in the Eppendorff tube during all experiments. The reaction was started with 2.5 uM of 32P ATP, and stopped with Traemmti sample buffer solution containing 30 uM EDTA. A minimum of five empty samples was counted in each experiment. The vacuums comprised a total analysis mixture minus one of the active components Ca2 +, CaM, MLC or MLCK. Experiments for which voids counts were higher than 300 cpm, were rejected. The phosphorylation was allowed to proceed for. 5 minutes and was evaluated counting 32P incorporated in MLC using a counted of liquid scintillation TM Analytic model 5303 Mark V. The signal comprised repetitive bursts of a
high frequency waveform. The amplitude remained constant at 0.2 G and the repetition rate was 1 burst / second for all exposures. The burst duration ranged from 65 useg to 1000 useg based on the SNR power analysis projections that showed that the optimal SNR Power would be achieved as the burst duration reached 500 useg. The results are shown in Figure 7 where the burst amplitude 701 in useg is plotted on the x axis and the myosin phosphorylation 702 as treated / simulated is plotted on the y axis. It can be seen that the effect of PMF on Ca2 + binding for CaM reaches its maximum at approximately 500 useg, just as illustrated by ß1 · SNR Power model. These results confirm that a PMF signal, configured in accordance with one embodiment of the present invention, would maximally increase myosin phosphorylation for sufficient burst durations to achieve an optimal SNR Power for a given magnetic field amplitude. Example 2 In accordance with one embodiment of the present invention, the use of an SNR Power model was further verified in an in vivo model of wound repair. A rat wound model has been well characterized both biomechanically and biochemically, and was used in this
study. Adult male Sprague Dawley rats weighing more than 300 grams were used. The animals were anesthetized with an intraperitoneal dose of ketamine 75 mg / kg and medetomidine 0.5 mg / kg. After achieving adequate anesthesia, the back was shaved, prepared with a dilute betadine / alcohol solution, and covered using a sterile technique. Using a # 10 scalpel, a 8 cm linear incision was made through the skin down to the area of the back of each rat. The edges of the Wound were dissected rounded to break all remaining fiber-dermal, leaving an open wound approximately 4 cm in diameter. Hemostasis was obtained by applying pressure to avoid any damage to the edges of the skin. The edges of the skin were then closed with a running Ethilon 4-0 suture. Postoperatively, the animals received 0.1-0 buprenorphine. Mg / kg, intraperitoneal. They were placed in individual cages and received food and water ad libitum. Exposure to PMF comprised two radio frequency pulse waveforms. The first was a clinical standard PRF signal comprising a burst of 65 useg of sine waves from 27.12 MHz to 1 Gauss in amplitude and repeating at 600 bursts / second. The second was a reconfigured PRF signal according to one embodiment of the present invention. For this signal the burst duration is
increased to 2000 useg and the amplitude and repetition rates were reduced to 0.2 G and to 5 bursts / second respectively. PRF was applied for 30 minutes twice a day. The tensile strength was made immediately after the excision of the wound. Two strips of skin 1 cm wide were transected perpendicular to the scar of each sample and used to measure the tensile strength in kg / mm2. Strips were extracted from the same area in each rat to ensure consistency in the measurement. The strips were then installed in a tensiometer. The strips were loaded at 10 mm / min and the maximum force generated before separating the wound was recorded. The final tensile strength for comparison was determined by taking the average of the maximum load in kilograms per mm2 of the two strips of the same wound. The results showed that the average tensile strength for the PRF signal of 65 useg 1 Gauss was 19.2 + 4.3 kg / mm2 for the exposed group against 13.0 + 3.5 kg / mm2 for the control group (p < .01) , which is an increase of 48%. In contrast, the average tensile strength for the PRF signal of 2000 useg 0.2 Gauss, configured in accordance with one embodiment of the present invention using an SNR Power model was 21.2 + 5.6 kg / mm2 for the
group treated against 13.7 + 4.1 kg / mm2 (p < .01) for the control group, which is an increase of 54%. The results for the two signals were not significantly different from each other. These results demonstrate that one embodiment of the present invention allowed to configure a new PRF signal that could be produced with significantly low power. The PRF signal configured in accordance with one embodiment of the present invention accelerated wound repair in the rat model in a low power manner against that for a clinical PRF signal that accelerated wound repair but required more than two orders of magnitude more power to be produced. Example 3 This example illustrates the effects of PRF electromagnetic fields selected by the SNR Power method in cultured neurons. Primary cultures were established from embryonic rodent mesencephalon 15-16 days. This area was dried, dissociated into single cells by mechanical trituration and the cells were plated either in defined medium or in medium with serum. The cells are typically treated after 6 days of culture, when the neurons have matured and developed mechanisms that make them vulnerable to biologically relevant toxins. After the
treatment, the conditioned medium is collected. Enzyme-linked immunosorbent assays ("ELISAs") are used for growth factors such as beta fibroblast growth factor ("FGFb") to quantify their release into the medium. Dopaminergic neurons are identified with an antibody to tyrosine hydroxylase ("TH"), an enzyme that converts amino acid tyrosine to L-dopa, the dopamine precursor, since dopaminergic neurons are the only cells that produce this enzyme in this system. The cells are quantified by counting the TH + cells in perpendicular strips through the culture dish under a magnification of 100 x. The serum contains nutrients and growth factors that support neuronal survival. The elimination of the serum induces the death of the neuronal cell. The culture medium was changed and the cells were exposed to PMF (power level 6, burst amplitude 3000 useg, and frequency 1 Hz). Four groups were used. Group 1 did not use exposure to PMF (null group). Group 2 used pre-treatment (PMF treatment 2 hours before the change of medium). Group 3 used post-treatment (PMF treatment 2 hours after the change of medium). Group 4 used immediate treatment (simultaneous PMF treatment at medium change). The results showed an increase of 46% in
the numbers of surviving dopaminergic neurons after 2 days when cultures were exposed to PMF prior to serum removal. Other treatment regimens had no significant effects on the numbers of surviving neurons. The results are shown in Figure 6 where the type of treatment is shown on the x-axis and the number of neurons is shown on the y-axis. Figure 7, where the treatment is shown on the x-axis and the number of neurons is shown on the y-axis, illustrates that the PMF D and E signals increase the numbers of dopaminergic neurons after reducing serum concentrations in the medium by 46% and 48% respectively. Both signals were configured with a burst amplitude of 3000 useg, and the repetition rates are 5 / sec and 1 / sec, respectively. Notably, signal D was administered in a chronic paradigm in this experiment, but signal E was administered only once: 2 hours prior to serum withdrawal, identical to experiment 1 (see above), producing effects of the same magnitude (46 % vs. 48%). Since the reduction of serum in the medium reduces the availability of nutrients and growth factors, the PMF induces the synthesis of release of these factors through the crops themselves. This portion of the experiment was performed to illustrate the effects of PMF-induced toxicity
OHDA, producing a highly characterized mechanism of dopaminergic cell death. This molecule is introduced to the cells by means of high affinity dopamine transporters and inhibits mitochondrial enzyme complex I, thus destroying these neurons by oxidative stress. The cultures were treated with 25 uM of ß-OHDA after chronic or acute PMF exposure paradigms. Figure 8 illustrates these results where it is shown in treatment on the x-axis and the number of neurons is shown on the y-axis. the toxin destroyed approximately 80% of the dopaminergic neurons in the absence of PMF treatment. One dose of PMF (power - 6, burst amplitude = 3000 useg, frequency = 1 / sec) significantly increased neuronal survival over ß-OHDA alone (2.6 times, p < .02). This result has a particular relevance in the development of neuroprotective strategies for Parkinson's disease, because 6-OHDA is used to injure dopaminergic neurons in the standard rodent model of Parkinson's disease, and the mechanism of toxicity is similar in some ways to the mechanism of neurodegeneration in Parkinson's disease itself. Example 4 In this example, electromagnetic field energy was used to stimulate neovascularization in an in vivo model. Two different signals were used, one
- -
configured according to the prior art and a second one configured according to one embodiment of the invention. One hundred eight male Sprague Dawley rats weighing approximately 300 grams each, were equally divided into nine groups. All animals were anesthetized with a ketamine / acepromazine / stanol mixture at 0.1 cc / g. using sterile surgical techniques, each animal had a segment of 12 cm to 14 cm of tail artery harvested using microsurgical technique. The artery was washed with 60 U / ml of heparinized saline to remove all the blood or emboli. These tail vessels, with an average diameter of 0.4 mm to 0.5 mm, were then sutured to the transected proximal and distal segments of the right femoral artery using two end-to-end anastomoses, creating a femoral arterial circuit. The resulting circuit was then placed in a subcutaneous bag created on the musculature of the abdominal wall / groin of the animal, and the incision in the groin was closed with Ethilon 4-0. Each animal was then placed randomly within one of the nine groups: groups 1 to 3 (controls), these rats received no treatment with electromagnetic field and were sacrificed at 4, 8 and 12 weeks; groups 4 to 6, received treatments of 30 minutes twice a day using electromagnetic fields of 0.1 Gauss during 4, 8
and 12 weeks (the animals were sacrificed at 4, 8 and 12 weeks, respectively); and groups 7 to 9 received 30-minute treatments twice a day using 2.0 Gauss electromagnetic fields for 4, 8 and 12 weeks (the animals were sacrificed at 4, 8 and 12 weeks, respectively). Pulsed electromagnetic energy was applied to the treated groups using a device constructed in accordance with an embodiment of the present invention. The animals in the experimental groups were treated for 30 minutes twice a day at either 0.1 Gauss or 2.0 Gauss, using short drives (2 msec at 20 msec) of 27.12 MHz. The animals were placed on top of the upper part of the applicator and they were confined to ensure that the treatment was applied properly. The rats were re-anesthetized with ketamine / acepromazine / statin intraperitoneally and 100 U / kg heparin intravenously. Using the previous inguinal incision, the femoral artery was identified and verified by power. The femoral artery / tail circuit was then isolated proximal and distally from the anastomosis sites, and the package was freed. Then the animals were sacrificed. The circuit was injected with saline followed by 0.5 ce to 1.0 ce of colored latex through a 25-gauge cannula and was clamped. The underlying abdominal skin was carefully resected, and the
arterial circuit was exposed. Neovascularization was quantified by measuring the surface area covered by new blood-vessel formation delineated by intial raluminal latex. All results were analyzed using the SPSS statistical analysis package. The most noticeable difference in neovascularization between rats treated versus untreated rats was presented at week 4. At that time, no new vessel formation was found among the controls, however, each of the treated groups had evidence Statistically similar significant of neovascularization at 0 cm2 versus 1.42 + 0.80 cm2 (p <0.001). These areas appeared with a leftover of latex segmentally distributed along the sides of the arterial circuit. At 8 weeks, controls began to demonstrate neovascularization measured at 0.7 + 0.82 cm2. Both groups treated at 8 weeks again had statistically significant blood vessel sprouts approximately equal (p <0.001) of 3.57 + 1.82 cm2 for the 0.1 Gauss group and 3.77 + 1.82 cm2 for the 2.0 Gauss group. At 12 weeks, the animals in the control group displayed 1.75 + 0.95 cm2 of neovascularization, while the 0.1 Gauss group showed 5.95 + 3.25 cm2, and the 2.0 Gauss group showed 6.20 + 3.95 cm2 of tree vessels. Again, both treated groups displayed comparable discoveries
- -
statistically significant (p <0.001) on the controls. These experimental findings demonstrate that the electromagnetic field stimulation of an isolated arterial circuit according to an embodiment of the present invention increases the amount of quantifiable neovascularization in a rat model in vivo. An increase in angiogenesis was demonstrated in each of the groups treated on each of the slaughter dates. No differences were found between the results of the two Gauss levels tested as predicted by the teachings of the present invention. Having described the modalities for an apparatus with integrated coil for therapeutically treating human and animal cells, tissues and organs with electromagnetic fields and a method for the use thereof, it is noted that modifications and variations can be made by persons skilled in the art to light of the previous teachings. Accordingly, it is understood that changes can be made to the particular embodiments of the disclosed invention, which are within the scope and essence of the invention as defined in the appended claims.
Claims (102)
- CLAIMS 1. A method for electromagnetic therapeutic treatment of animals and humans, comprising the steps of: configuring at least one waveform according to a mathematical model having at least one waveform parameter, for coupling said at least one waveform to an objective path structure; selecting a value of said at least one waveform parameter such that said at least one waveform is configured to be detectable in said target path structure above the background activity in said target path structure; generating an electromagnetic signal from said at least one configured waveform; integrating at least one coupling device with a positioning device to place it in proximity to said target path structure; and coupling said electromagnetic signal to said target path structure using said at least one coupling device. The method of claim 1, wherein said at least one waveform parameter includes at least one of a frequency component parameter that configures said at least one waveform to be repeated between - - approximately 0.01 Hz and approximately 100 MHz, a burst amplitude envelope parameter that follows a mathematically defined amplitude function, a burst amplitude parameter that varies in each repetition according to a mathematically defined amplitude function, a peak parameter of induced electric field that varies between approximately 1 μ? / cm and approximately 100 mV / cm in said objective path structure according to a mathematically defined function, and a magnetic magnetic field peak parameter that varies between approximately 1 μ? and approximately 0.1 T in said objective path structure according to a mathematically defined function. The method of claim 2, wherein said defined amplitude function includes at least one of a function of 1 / frequency, a logarithmic function, a chaotic function and an exponential function. The method of claim 1, wherein said step of selecting a value of at least one waveform parameter further includes the step of selecting a value from said at least one waveform parameter to satisfy a proportion model. signal to noise. The method of claim 1, wherein said step of selecting a value of at least one waveform parameter further includes the step of selecting a value of said at least one waveform parameter for - - satisfy a model of power to noise signal ratio. The method of claim 1, wherein said target pathway structure includes at least one of molecules, cells, tissues, organs, ions and ligands. The method of claim 1, further comprising the step of attaching ions and ligands to regulatory molecules to improve growth, repair and maintenance of tissues. The method of claim 7, wherein said binding of ions and ligands includes modulating the binding of calcium to calmodulin. The method of claim 7, wherein said binding of ions and ligands includes modulating the production of the growth factor in target path structures. 10. The method of claim 7, wherein said binding of ions and ligands includes modulating cytokine production in target pathway structures. The method of claim 7, wherein said binding of ions and ligands includes modulating the growth factors and cytokines relevant for the growth, repair and maintenance of tissues. The method of claim 7, wherein said binding of ions and ligands includes modulating angiogenesis and neovascularization for the growth, repair and maintenance of target pathway structures. - - 13. The method of claim 7, wherein said binding of ions and ligands includes modulating angiogenesis and neovascularization for the treatment of cerebrovascular disease. 14. The method of claim 7, wherein said binding of ions and ligands includes modulating growth factors and cytokines for the treatment of sleep disorders. The method of claim 7, wherein said binding of ions and ligands includes modulating angiogenesis and neovascularization for the treatment of sleep disorders. 16. The method of claim 7, wherein said binding of ions and ligands includes modulating the release of human growth hormone by increasing the duration of the deep sleep stages. The method of claim 1, further comprising the step of applying pharmacological and herbal agents to target pathway structures for growth, repair and maintenance of tissues. The method of claim 17, wherein said pharmacological and herbal agents include at least one of topical drugs, topical creams and topical ointments. 19. The method of claim 1, further comprising the step of applying pharmacological agents and Herbal to target pathway structures for the treatment of neurodegenerative diseases. 20. The method of claim 1, wherein said positioning device includes at least one of therapeutic surfaces, therapeutic structures, therapeutic devices, surgical ap- plices, anatomical supports, anatomical covers, wound dressings, pads, seating arrangements, cushions. for mattresses, shoes, wheelchairs, chairs, clothing, articles and support structures that can be placed in proximity to tissue and living cells. The electromagnetic treatment apparatus of claim 20, wherein said garment includes at least one of clothing, fashion accessories, shoes, socks and footwear. 22. The method of claim 1, wherein said coupling device includes at least one of a conductive thread and coil. 23. The method of claim 1, further comprising the step of applying standard modalities of physical therapy for the treatment of a body area. The method of claim 23, wherein the standard modalities of physical therapy include at least one of heat, cold, compression, massage and exercise. 25. The method of claim 1, further comprising the step of simultaneously generating said electromagnetic signal to a plurality of said at least one coupling device. 26. The method of claim 25, wherein said electromagnetic signal is generated from at least one of, identically configuring said at least one waveform, and differently configuring said at least one waveform. The method of claim 1, further comprising the step of sequentially generating an electromagnetic signal to a plurality of said at least one coupling device. The method of claim 27, wherein said electromagnetic signal is generated from at least one of, identically configuring said at least one waveform, and differently configuring said at least one waveform. 29. The method of claim 1, further comprising the step of multiplexing an electromagnetic signal for a plurality of said at least one coupling device. 30. The method of claim 29, wherein said electromagnetic signal is generated from at least one of, identical to at least one of said waveforms. configured, and different from at least one of said configured waveforms. 31. The method of claim 1, which further comprises the step of using at least one of the standard medical therapies and non-standard medical therapies in conjunction with said inductive apparatus for electromagnetic treatment. 32. The method of claim 31, wherein standard medical therapies include at least one of tissue transplants and organ transplants. The method of claim 1, further comprising the step of using at least one of the standard physical therapies and non-standard physical therapies in conjunction with said inductive apparatus for electromagnetic treatment. 34. The method of claim 33, wherein the standard physical therapies include at least one of ultrasound, negative pressure, positive pressure, heat, cold, massage, exercise and acupuncture. 35. The method of claim 1, wherein the step of coupling said electromagnetic signal to said target path structure includes coupling to prevent the loss and deterioration of cells and tissues. 36. The method of claim 1, wherein the step of coupling said electromagnetic signal to said Target pathway structure includes coupling to increase the activity of cells and tissues. 37. The method of claim 1, wherein the step of coupling said electromagnetic signal to said target path structure includes coupling to increase the cell population. 38. The method of claim 1, wherein the step of coupling said electromagnetic signal to said target path structure includes coupling to prevent neuronal deterioration. 39. The method of claim 1, wherein the step of coupling said electromagnetic signal to said target path structure includes coupling to increase the population of neurons. 40. The method of claim 1, wherein the step of coupling said electromagnetic signal to said objective pathway structure includes coupling to prevent neuronal adrenergic damage. 41. The method of claim 1, wherein the step of coupling said electromagnetic signal to said target pathway structure includes coupling to increase the population of adrenergic neurons. 42. The method of claim 1, wherein the step of generating an electromagnetic signal from said at least one configured waveform includes generating programmable said electromagnetic signal. 43. An apparatus for electromagnetic treatment for animals and humans, comprising: a waveform configuration means for configuring at least one waveform to be coupled to a target path structure according to a mathematical model having at least one a waveform parameter capable of being selected such that said at least one waveform is configured to be detectable in said target structure above the background activity in said target path structure; at least one coupling device connected to said waveform configuration means by at least one. connection means for generating an electromagnetic signal from said at least one configured waveform and for coupling said electromagnetic signal to said objective path structure; and a positioning device, wherein said at least one coupling device is integral with said positioning device. 44. The electromagnetic treatment apparatus of claim 43, wherein said at least one waveform parameter includes at least one of a frequency component parameter that configures said at least one waveform to be repeated between approximately 0.01 Hz and approximately 100 MHz, according to a mathematical function, a burst amplitude envelope parameter that follows a mathematically defined amplitude function, a burst amplitude parameter that varies in each repetition according to a mathematically defined amplitude function, a electric induced field peak parameter that varies between approximately 1 μ? / cm and approximately 100 mV / cm in said objective path structure according to a mathematically defined function, and a magnetic magnetic field peak parameter that varies between approximately 1 μ ? and approximately 0.1 T in said objective path structure according to a mathematically defined function. 45. The electromagnetic treatment apparatus of claim 43, wherein said defined amplitude function includes at least one of a function of 1 / frequency, a logarithmic function, a chaotic function, and an exponential function. 46. The electromagnetic treatment apparatus of claim 43, wherein said value of at least one waveform parameter further includes a value of said at least one waveform parameter to satisfy a signal-to-noise ratio model. 47. The electromagnetic treatment apparatus of claim 43, wherein said value of at least one The waveform parameter further includes a value of said at least one waveform parameter to satisfy a power-to-noise signal ratio model. 48. The electromagnetic treatment apparatus of claim 43, wherein said target pathway structure includes at least one of molecules, cells, tissues, organs, ions and ligands. 49. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target pathway structure where the binding of calcium to calmodulin is modulated. 50. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure where the binding of calcium to calmodulin is modulated. 51. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target pathway structure to modulate at least one of the growth factor and cytokine production, relevant for growth, repair, and maintenance of said objective path structure. 52. The apparatus for electromagnetic treatment of claim 51, wherein the growth factor includes at least one of growth factors of fibroblasts, growth factors derived from platelets and interleukin growth factors. 53. The apparatus for electromagnetic treatment of claim 43, wherein the signal is capacitively coupled to said target path structure to modulate at least one of the growth factor and cytokine production, relevant to the growth, repair, and maintenance of said target pathway structure. 54. The electromagnetic treatment apparatus of claim 53, wherein the growth factor includes at least one of fibroblast growth, platelet derived growth factors and interleukin growth factors. 55. The apparatus for electromagnetic treatment of claim 43, wherein the signal is capacitively coupled to said target pathway to modulate angiogenesis and neovascularization for the treatment of bone fractures. 56. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target via structure to modulate angiogenesis and neovascularization for the treatment of bone fractures. 57. The device for electromagnetic treatment - - of claim 43, wherein the signal is inductively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of diseases. 58. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of diseases. 59. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of vascular disease. 60. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of vascular disease. 61. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of neurodegenerative diseases. 62. The device for electromagnetic treatment of claim 43, wherein the signal is inductively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of sleep disorders. 63. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure to modulate angiogenesis and neovascularization for the treatment of sleep disorders. 64. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said objective pathway structure to modulate the production of human growth factor by increasing the periods of deep sleep. 65. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target pathway structure to modulate the production of human growth factor by increasing the periods of deep sleep. 66. The electromagnetic treatment apparatus of claim 43, wherein the electromagnetic treatment apparatus is configured to be lightweight and portable. 67. The electromagnetic treatment apparatus of claim 43, wherein the device of positioning includes at least one of therapeutic surfaces, therapeutic structures, therapeutic devices, surgical appositories, anatomical supports, anatomical covers, wound dressings, pads, seating arrangements, cushions for mattresses, shoes, wheelchairs, chairs, clothing, articles and support structures that can be placed in proximity to tissue and living cells. 68. The electromagnetic treatment apparatus of claim 67, wherein said garment includes at least one of garments, accessories, shoes, socks and footwear. 69. The electromagnetic treatment apparatus of claim 43, wherein said connection means includes at least one of cable, wireless means of transmitting and receiving signal and direct connection means. 70. The electromagnetic treatment apparatus of claim 43, wherein the waveform configuration means is programmable. 71. The electromagnetic treatment apparatus of claim 43, wherein the waveform configuration means provides at least one pulsed magnetic signal for a predetermined time. 72. The device for electromagnetic treatment of claim 43, wherein the waveform configuration means provides at least one pulsed magnetic signal for a random time. 73. The apparatus for electromagnetic treatment of claim 43, which further comprises a means of delivery for standard modalities of physical therapy. 74. The electromagnetic treatment apparatus of claim 73, wherein said standard modalities of physical therapy include heat, cold, massage and exercise. 75. The electromagnetic treatment apparatus of claim 43, further comprising a delivery means for pharmacological agents and herbal agents. 76. The electromagnetic treatment apparatus of claim 43, further comprising a delivery means for standard medical treatments. 77. The electromagnetic treatment apparatus of claim 76, wherein the standard medical treatments include at least one of treatments for neovascularization, angiogenesis, immune response for malignant and benign conditions and transudation. 78. The electromagnetic treatment apparatus of claim 43, wherein said waveform configuration means is integrated with said positioning device. · 79. The device for electromagnetic treatment - - of claim 43, wherein said positioning device is at least one portable, implantable, disposable. 80. The electromagnetic treatment apparatus of claim 43, further comprising a plurality of at least one coupling device configured to simultaneously generate at least one electromagnetic signal from at least one configured waveform. 81. The electromagnetic treatment apparatus of claim 80, wherein said at least one configured waveform includes at least one of identical to said at least one of the configured waveforms and different from said at least one of the forms of wave configured. 82. The electromagnetic treatment apparatus of claim 43, further comprising a plurality of at least one coupling device configured to sequentially generate at least one electromagnetic signal from at least one configured waveform. 83. The electromagnetic treatment apparatus of claim 82, wherein said at least one configured waveform includes at least one of identical to said at least one of the configured waveforms and different from said at least one of the forms of wave configured. 84. The electromagnetic treatment apparatus of claim 43, further comprising a plurality of at least one coupling device configured to multiplex at least one electromagnetic signal from at least one configured waveform. 85. The electromagnetic treatment apparatus of claim 84, wherein said at least one configured waveform includes at least one of identical to said at least one of the waveforms configured and different from said at least one of the forms of wave configured. 86. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target path structure. 87. The apparatus for electromagnetic treatment of claim 43 ,. wherein the signal is capacitively coupled to said objective path structure. 88. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target path structure to prevent loss and deterioration of cells and tissues. 89. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target path structure to prevent loss and deterioration of cells and tissues. 90. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target pathway structure to increase cellular activity. 91. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target path structure to increase cellular activity. 92. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target path structure to increase the cell population. 93. The apparatus for electromagnetic treatment of claim 43, wherein the signal is capacitively coupled to said target path structure to increase the cell population. 94. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said target path structure to prevent deterioration of the neurons. 95. The apparatus for electromagnetic treatment of claim 43, wherein the signal is capacitively coupled to said target path structure to prevent deterioration of the neurons. 96. The device for electromagnetic treatment of claim 43, wherein the signal is inductively coupled to said target pathway structure to increase the population of neurons. 97. The apparatus for electromagnetic treatment of claim 43, wherein the signal is capacitively coupled to said target path structure to increase the population of neurons. 98. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said objective pathway structure to prevent deterioration of the adrenergic neurons. 99. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said target path structure to prevent deterioration of the adrenergic neurons. 100. The electromagnetic treatment apparatus of claim 43, wherein the signal is inductively coupled to said targeting structure to increase the population of adrenergic neurons. 101. The electromagnetic treatment apparatus of claim 43, wherein the signal is capacitively coupled to said via structure. objective to increase the population of adrenergic neurons. 102. The electromagnetic treatment apparatus of claim 43, wherein said waveform configuration means is programmable.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008003378A true MX2008003378A (en) | 2008-10-03 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7758490B2 (en) | Integrated coil apparatus for therapeutically treating human and animal cells, tissues and organs with electromagnetic fields and method for using same | |
| US8415123B2 (en) | Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells | |
| US20180104505A1 (en) | Apparatus and method for electromagnetic treatment | |
| US7740574B2 (en) | Electromagnetic treatment induction apparatus and method for using same | |
| US20080058793A1 (en) | Electromagnetic apparatus for prophylaxis and repair of ophthalmic tissue and method for using same | |
| US20070173904A1 (en) | Self-contained electromagnetic apparatus for treatment of molecules, cells, tissues, and organs within a cerebrofacial area and method for using same | |
| US20060212077A1 (en) | Electromagnetic treatment apparatus for augmenting wound repair and method for using same | |
| EP2066393A1 (en) | Electromagnetic apparatus for respiratory disease and method for using same | |
| WO2006096698A2 (en) | Pharmacological, chemical, and topical agent enhancement apparatus and method for using same | |
| MX2008003378A (en) | Integrated coil apparatus and method for using same | |
| AU2005336126A1 (en) | Integrated coil apparatus and method for using same | |
| KR20070015908A (en) | Electromagnetic therapy apparatus and method |